Skip to content
TrialScanner

NCT03260023

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

Phase 1/Phase 2Active, not recruitingPFECollaborator

Registry record

Lead sponsor
Transgene
Conditions
HPV-Related Carcinoma; HPV-Related Cervical Carcinoma; HPV-Related Anal Squamous Cell Carcinoma; HPV-Related Penile Squamous Cell Carcinoma; HPV-Related Vulvar Squamous Cell Carcinoma
Primary completion
Sep 18, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03260023 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03260023: Phase Ib/II of TG4001 and... | TrialScanner